Literature DB >> 19574208

Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles.

Bella Pajares-Hachero1, Esperanza Torres, Isabel Hierro, José Miguel Jurado, Antonio Rueda.   

Abstract

Mantle cell lymphoma (MCL) is an entity which exceptionally affects the ocular region and periorbital tissues, but which should be included in the differential diagnosis of lesions which affect the orbital region in a diffused manner. We report the case of a 60-year-old patient diagnosed with stage IV MCL, whose fi rst clinical manifestation was a result of the damage of lacrimal glands, retro-orbital tissue and ocular motor muscles. The patient was treated with rituximab and chemotherapy, achieving a complete response of those lesions.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19574208     DOI： 10.1007/s12094-009-0389-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  7 in total

1.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Authors:  Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

Review 2.  Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors.

Authors:  Jérôme Meunier; Livia Lumbroso-Le Rouic; Anne Vincent-Salomon; Rémy Dendale; Bernard Asselain; Philippe Arnaud; Alain Fourquet; Laurence Desjardins; Corine Plancher; Patricia Validire; Driss Chaoui; Christine Lévy; Didier Decaudin
Journal:  Hematol Oncol       Date:  2004-12       Impact factor: 5.271

3.  Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

Authors:  B S Kahl; W L Longo; J C Eickhoff; J Zehnder; C Jones; J Blank; T McFarland; W Bottner; H Rezazedeh; J Werndli; H H Bailey
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

4.  Mantle cell lymphoma in the ocular adnexal region.

Authors:  Audrey Looi; Randy D Gascoyne; Mukesh Chhanabhai; Joseph M Connors; Jack Rootman; Valerie A White
Journal:  Ophthalmology       Date:  2005-01       Impact factor: 12.079

Review 5.  The cellular origin of mantle cell lymphoma.

Authors:  Francesco Bertoni; Maurilio Ponzoni
Journal:  Int J Biochem Cell Biol       Date:  2007-05-10       Impact factor: 5.085

Review 6.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

7.  The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Roswitha Forstpointner; Martin Dreyling; Roland Repp; Sandra Hermann; Annette Hänel; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Robert Rohrberg; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.